Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1HER2-positive Gastric Cancer 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 15Paclitaxel 15Carboplatin 13Specimen Handling 6Biopsy 6durvalumab 5Magnetic Resonance Spectroscopy 5dostarlimab 4Taxes 4Surveys and Questionnaires 4Observation 4Letrozole 4Everolimus 4Cisplatin 4olaparib 3lenvatinib 3ceralasertib 3Doxorubicin 3sacituzumab govitecan 2pertuzumab 2copanlisib 2cabozantinib 2atezolizumab 2abemaciclib 2Trastuzumab 2Robotic Surgical Procedures 2Pemetrexed 2Nivolumab 2Metformin 2Megestrol Acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Endometrial Neoplasms × disitamab vedotin × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡